Abstract
The use of targeted radionuclide-tagged vector molecules forms the basis of the foundation of the emerging science of nuclear medicine. These vector molecules play a pivotal role in screening the extent of disease spread in cancer patients. Chemokine receptor 4 (CXCR4) overexpression is noted in > 75% of cancers such as breast cancer, lymphoma, lung cancer, etc. Plerixafor is a CXCR4 antagonist used to mobilize hematopoietic stem cells. It binds to CXCR4 by three acidic residues in binding pockets Asp171, Asp262, and Glu288.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
